Literature DB >> 3871644

Human bone marrow and peripheral blood T lymphocyte depletion: efficacy and effects of both T cells and monocytes on growth of hematopoietic progenitors.

L Levitt, T J Kipps, E G Engleman, P L Greenberg.   

Abstract

The efficacy of four separate methods of human bone marrow T lymphocyte depletion was assessed, and the effect of T cells and monocytes on in vitro growth of marrow (CFU-GEMM, BFU-E, and CFU-GM) and peripheral blood (BFU-E) hematopoietic progenitors was determined. Extent of T cell depletion was assessed by multiparameter fluorescent cell sorter (FACS) analysis and by functional studies. Cells staining positively by FACS analysis for one or more of three separate fluorescent pan-T cell monoclonal antibodies (MCAbs) comprised 8.4% to 9.5% of control marrow mononuclear cells (MNCs). T cells constituted 3.2% to 5.1% of marrow following single, sequential, or combination treatment with two different pan-T cell MCAbs (Leu 1 and TM1) plus complement, 1.5% to 2.2% of marrow following solid-phase immunoabsorption ("panning"), 0.2% of marrow after sheep cell rosetting, and only 0.05% of marrow after FACS selective cell sorting and gated separation. T cells made up 59% to 73% of control peripheral blood MNCs and 0.8% to 2.8% of peripheral MNCs following sheep cell rosetting plus treatment with Leu 1 MCAb and complement. Mitogen (PHA, Con A) and allogeneic MLC-induced blastogenic responses (stimulation indices, experimental/control or E/C) revealed a concordant decrement in marrow T cell function after MCAb plus complement (E/C of 3.9 to 9.0), after panning (E/C of 1.6 to 3.5) and after sheep cell rosetting (E/C of 0.7 to 1.3), compared with control marrow (E/C of 5.3 to 15.7). After T cell depletion, marrow BFU-E growth was 95% to 120% of control, CFU-GM growth was 90% to 108% of control, and CFU-GEMM growth was 89% to 111% of control. Marrow T cell and/or monocyte depletion did not alter erythropoietin-dependent BFU-E growth in the absence of Mo-conditioned medium (81% to 95% of control), and the addition of as many as 50 to 100 X 10(3) purified marrow monocytes or T cells to 10(5) autologous nonadherent T cell-depleted marrow target cells had a negligible (P greater than .1) effect on marrow BFU-E growth in vitro. Peripheral blood (PB) BFU-E/10(5) T-depleted target cells were 106% +/- 19% of expected; PB BFU-E growth was significantly diminished after monocyte depletion alone (7% +/- 6% of expected) or after monocyte plus T cell depletion (8% +/- 4% of expected).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3871644

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Enhancement of bone marrow allografts from nude mice into mismatched recipients by T cells void of graft-versus-host activity.

Authors:  T Lapidot; I Lubin; A Terenzi; Y Faktorowich; P Erlich; Y Reisner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

2.  Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.

Authors:  L J Levitt; A Nagler; F Lee; J Abrams; M Shatsky; D Thompson
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

3.  Impaired in vitro growth of peripheral blood hematopoietic progenitor cells in HIV-infected patients: evidence of an inhibitory effect of autologous T lymphocytes.

Authors:  E Balleari; S Timitilli; F Puppo; L Gaffuri; C Musselli; F Rizzo; F Indiveri; R Ghio
Journal:  Ann Hematol       Date:  1991-12       Impact factor: 3.673

4.  Defective in vitro growth of the hemopoietic progenitor cells in the acquired immunodeficiency syndrome.

Authors:  C C Stella; A Ganser; D Hoelzer
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

5.  Interleukin 1 stimulates granulocyte macrophage colony-stimulating activity release by vascular endothelial cells.

Authors:  G C Bagby; C A Dinarello; P Wallace; C Wagner; S Hefeneider; E McCall
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

6.  Human T cell leukemia virus-I-associated T-suppressor cell inhibition of erythropoiesis in a patient with pure red cell aplasia and chronic T gamma-lymphoproliferative disease.

Authors:  L J Levitt; G R Reyes; D K Moonka; K Bensch; R A Miller; E G Engleman
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

7.  Differential regulation of lymphokine production by distinct subunits of the T cell interleukin 2 receptor.

Authors:  S Burdach; N Zessack; D Dilloo; M Shatsky; D Thompson; L Levitt
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.